CFMS Conformis

Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation

Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation

Conformis and Bodycad Settle Litigation Related to Bodycad’s Patient-Specific Instruments and Implants

BILLERICA, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) along with Bodycad Laboratories, Inc. and Bodycad USA Corp. announced today that they have entered into a settlement and license agreement that resolves the patent infringement dispute filed by Conformis in June of 2021.

Conformis and Bodycad are pleased to have resolved their ongoing patent litigation. The companies have amicably agreed to an undisclosed amount for the dismissal of all patent litigation between the companies along with a release and license to certain Conformis patents related to patient-specific instrumentation and knee implants.

About Conformis, Inc.

Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program, as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit . To receive future releases in e-mail alerts, sign up at ir.conformis.com.

CONTACT:

Investor Contact

 

+1 (781) 374-5598

About Bodycad Laboratories, Inc.

Bodycad is a Canadian company that is transforming the current standards in orthopaedic implants to help surgeons and patients achieve their mutual goal of a perfect Personalized Restoration™. With the help of Bodycad’s proprietary software, its integrated planning process as well as its fully vertically integrated manufacturing facility, surgeons can quickly and efficiently achieve specific design plans and personalized restorations based on the precise anatomical specifications of their patients. Bodycad’s unique approach offers patients and surgeons the potential of greater comfort, fit and durability, thereby making the pursuit of orthopaedic perfection possible. Learn more at .

CONTACT:

Corporate Headquarters

+1 (866) 527-1388

 



EN
15/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conformis

 PRESS RELEASE

restor3d Completes Acquisition of Conformis

restor3d Completes Acquisition of Conformis Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased tr...

 PRESS RELEASE

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conform...

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, und...

 PRESS RELEASE

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders ...

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will a...

 PRESS RELEASE

Conformis Reports Second Quarter 2023 Financial Results

Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue ...

 PRESS RELEASE

Conformis Announces Definitive Agreement to be Acquired by restor3d fo...

Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash Combination creates a leading personalized 3D-printed orthopedic medical device company DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approxi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch